SynthesisInternational journal of clinical pharmacy2026
Toward standardized outcome reporting in pneumonia: an overview of systematic reviews of antimicrobial therapy.
Synthesis in International journal of clinical pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPneumonia is a leading cause of morbidity and mortality worldwide, with community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP) representing the two most common subtypes. Antimicrobials are central to treatment; however, systematic reviews (SRs) evaluating their use have reported highly variable outcomes, limiting evidence synthesis and comparability. The development of a core outcome set (COS) may address this gap.
aimTo summarize the primary outcomes reported in SRs of antimicrobials for adult pneumonia and to construct an preliminary list of candidate outcomes to inform COS development.
methodA systematic search was performed in PubMed, Embase, Cochrane Library, CNKI, Wanfang Data, and China Science and Technology Journal Database from inception to December 2024. Eligible studies included SRs or meta-analyses that evaluated antimicrobial therapy in adults (≥ 18 years) with CAP or HAP. Two reviewers independently screened the studies, extracted data on the study characteristics, pneumonia type, severity assessment tools, and outcomes. The Corrected Covered Area (CCA) was calculated to quantify the overlap in primary outcome reporting. Outcomes were grouped by pneumonia type and severity and categorized into five domains following the COMET taxonomy.
resultsA total of 97 SRs were included. Twenty-one distinct primary outcomes were identified, with limited overlap. Mortality and clinical success were the most frequently reported outcomes, though inconsistently defined across studies. Significant variability was noted in the definitions and time points of outcomes, as well as in severity assessment tools. Registered SRs reported fewer outcomes than non-registered ones.
conclusionThere is considerable variation in primary outcome reporting in antimicrobial SRs for adult pneumonia. Mortality and clinical success are the most commonly reported outcomes, but their definitions lack consistency. Developing subtype- and severity-specific COS is crucial for standardizing outcome reporting and improving evidence synthesis.
Indexed as
Identifiers
41284209What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.